Graphene-incorporated hyaluronic acid-based hydrogel as a controlled Senexin A delivery system.

• DOI: 10.12336/biomatertransl.2022.02.007
• Publication Date: 2022-01-01
• Authors: Panita Maturavong...; Weiwei Wu; Jingyu Fan; Igor B. Roninson; Taixing Cui; Qian Wang
• Keywords: Targeted drug delivery

Perivascular delivery of therapeutic agents against established aetiologies for occlusive vascular remodelling has great potential vein graft failure. However, none the perivascular drug systems tested experimentally have been translated into clinical practice. In this study, we a novel strategy to locally and sustainably deliver cyclin-dependent kinase 8/19 inhibitor Senexin A (SenA), an emerging candidate treat disease, using graphene oxide-hybridised hyaluronic acid-based hydrogels. We demonstrated approach accommodate SenA in hydrogels through utilising oxide nanosheets allowing non-covalent interaction with SenA. The resulting produced sustained over 21 days tunable release kinetics. vitro assays also that were biocompatible. This oxide-incorporated acid hydrogel offers optimistic outlook as system treating diseases, such